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Co-crystalized fragment sized PDE inhibitors
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ChEMBL Analysis
ChEMBL was mined for fragment sized inhibitors with an IC50 or Ki value registered as "=" against one of the ChEMBL target IDs listed below. 
Human PDEs
Descriptor Calculation
Prior to descriptor calculations all compounds were prepared using Ligprep. 1
All descriptors were calculated using QikProp 2 . QikProp considers only neutral molecules, therefore molecules that are inherently charged (i.e. quaternary amines) will not be included in the analysis.
1. Schrödinger Release 2015-4: LigPrep, Schrödinger, LLC, New York, NY, 2015.
2. Schrödinger Release 2015-4: QikProp, Schrödinger, LLC, New York, NY, 2015.
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Properties of analysed fragments Figure S1 . Calculated properties for fragment sized ligands in the PDB co-crystalized with a PDE.
S9 Figure S2 . Calculated molecular properties for the PDE inhibitory fragments extracted from ChEMBL. Table S2 . The number of crystal structures with a fragment sized inhibitor co-crystallized in the PDB, listed by PDE. Table S3 . Number of activities reported in ChEMBL for fragment sized molecules against the respective PDE.
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